Enliven Therapeutics, Inc. (ELVN)

Enliven Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	98.9	124.12	100.14	75.54	48.31
Short-Term Investments	363.73	189.32	153.01	-	41.97
Cash & Short-Term Investments	462.62	313.44	253.15	75.54	90.28
Cash Growth	47.59%	23.82%	235.14%	-16.33%	2.33%
Other Current Assets	12.26	4.69	13	2.22	2.42
Total Current Assets	474.88	318.13	266.15	77.75	92.7
Net Property, Plant & Equipment	0.42	0.46	1.06	1.52	0.78
Other Long-Term Assets	0.87	7.18	4.65	4.03	0.18
Total Assets	476.17	325.76	271.87	83.3	93.65
Accounts Payable	2.16	1.34	0.53	3.44	2.36
Accrued Expenses	14.41	14.57	15.36	6.28	4.6
Current Portion of Leases	-	-	-	-	0.25
Other Current Liabilities	-	-	10	-	-
Total Current Liabilities	16.57	15.92	25.89	9.72	7.21
Long-Term Leases	-	-	-	-	0.41
Other Long-Term Liabilities	-	-	0.07	0.66	-
Total Long-Term Liabilities	-	-	0.07	0.66	0.41
Total Liabilities	16.57	15.92	25.96	10.37	7.62
Common Stock	0.06	0.05	0.04	0	0.03
Additional Paid-in Capital	806.37	553.21	400.17	6.04	233.52
Accumulated Other Comprehensive Income	0.33	0.06	0.14	-	-0.02
Retained Earnings	-347.17	-243.47	-154.45	-82.86	-147.5
Total Common Shareholders' Equity	459.6	309.85	245.91	-76.83	86.03
Minority Interest	-	-	-	149.75	-
Shareholders' Equity	459.6	309.85	245.91	72.92	86.03
Total Liabilities & Equity	476.17	325.76	271.87	83.3	93.65
Total Debt	0	0	0	0	0.65
Net Cash (Debt)	462.62	313.44	253.15	75.54	89.63
Net Cash Growth	47.59%	23.82%	235.14%	-15.72%	1.59%
Net Cash Per Share	8.16	6.66	7.12	24.18	16.55
Book Value	459.6	309.85	245.91	-76.83	86.03
Book Value Per Share	8.11	6.58	6.92	-24.59	15.89
Tangible Book Value	459.6	309.85	245.91	-76.83	86.03
Tangible Book Value Per Share	8.11	6.58	6.92	-24.59	15.89

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q